Missing family's boat found in Alaska waters along with human remains
ANCHORAGE, Alaska (AP) — Nearly a year after the U.S. Coast Guard suspended the search for a family of four missing after the boat they were on capsized in waters off south-central Alaska, the vessel along with human remains have been found, officials said Wednesday.
The discovery came after three private Alaska companies, including one that uses sonar equipment to search underwater, offered in April to help look for the family, who are from Texas, according to a statement released by the Alaska Department of Public Safety.
Earlier this month, they found the missing boat along with human remains in 180 feet (55 meters) of water in Kachemak Bay near Homer, the department said.
Divers from the state were then able to recover three sets of remains from the sunken vessel during dives on Tuesday and Wednesday.
The remains have been taken to the State Medical Examiner's Office to perform autopsies and identify them, according to the public safety department. It did not say how long identifying the remains would take.
The missing family from Troy, Texas, includes Mary Maynard, 37, and David Maynard, 42, along with sons Colton, 11, and Brantley, 8, according to the statement.
The search for the family was launched in August after a report came in that a 28-foot (8.5-meter) aluminum boat carrying eight people had begun taking on water, the U.S. Coast Guard said at the time. The Coast Guard notified other ships in the area of the situation, and a boat nearby rescued four people.
The Coast Guard scoured Kachemak Bay and Alaska search and rescue crews tried to use sonar equipment to find the family, according to the state's public safety department. But they were not successful and by the next evening, the search was suspended.
Christi Wells, who provided a statement on behalf of Mary Maynard's parents at the time, said the family enjoyed spending time with friends and relatives, and traveling, according to the Anchorage Daily News. Mary Maynard was a traveling nurse and David Maynard stayed at home with the children and had a lawn care business, she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
29 minutes ago
- Associated Press
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline Results support commitment to enhance clinical understanding of chronic diseases in communities of color TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent® (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones. The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones. The data were shared in an oral presentation at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference. 'Atopic dermatitis, a chronic disease with underlying type 2 inflammation, has a high prevalence and quality of life impact on patients with skin of color. Unique clinical features like darker patches of hyperpigmentation versus redness typically seen on lighter skin may lead to less accurate diagnoses and underestimation of disease severity,' said Andrew Alexis, M.D., M.P.H., Professor of Clinical Dermatology at Weill Cornell Medicine. 'The results from the DISCOVER trial showed that Dupixent patients with atopic dermatitis and darker skin not only experienced reduced disease severity and itch but also saw improvements in areas of particular concern including dyspigmentation and dry skin. These data deepen the clinical understanding of atopic dermatitis within this underserved population, including use of newly validated scales.' In the trial, 120 patients with atopic dermatitis and skin of color (82% Black, 11% Asian, 2% American Indian/Alaska Native, 5% Arab, Central American or other) were treated with Dupixent every two weeks using a weight-based dosing regimen. At 24 weeks: The safety results in the DISCOVER trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indications. The overall rate of adverse events (AEs; n=124) in the DISCOVER trial was 42%, with the most common (≥2%) AEs being headache (3%), upper respiratory tract infection (2%), eczema (2%), conjunctivitis (3%) and allergic conjunctivitis (2%). About Atopic Dermatitis in Skin of Color Atopic dermatitis is a chronic skin disease with underlying type 2 inflammation that causes intense, persistent itch and skin lesions that cover much of the body, resulting in skin dryness, cracking, pain, crusting and oozing. In patients with skin of color, the type and location of the lesions can vary, and they are more likely to have hardened skin lesions and severe skin dryness, itch, dyspigmentation and greater disease severity than those with lighter skin. Additionally, redness that is observed on lighter skin typically appears as darkened, grey or violet on darker skin tones. Because the disease presents differently in people with skin of color, it can be misdiagnosed or the severity underestimated, which can contribute to higher levels of healthcare resource utilization. About the DISCOVER Clinical Trial The DISCOVER Phase 4 open-label, single-arm trial evaluated the efficacy and safety of Dupixent in adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis and skin of color, as defined by Fitzpatrick skin types IV-VI (those with high melanin; light brown to black). During the 24-week treatment period, all patients in the trial received Dupixent monotherapy every two weeks based on weight after a loading dose: patients weighing ≥30 to <60 kg received 200 mg and patients weighing ≥60 kg received 300 mg. The primary endpoint assessed the proportion of patients who achieved at least 75% improvement on the Eczema Area and Severity Index (EASI-75) at 24 weeks. Secondary endpoints included the proportion of patients who achieved ≥4-point improvement on the Peak-Pruritus Numerical Rating Scale (PP-NRS) at 24 weeks. Additional endpoints included pigmentary changes on the clinician-reported Post-Inflammatory Hyperpigmentation Severity Scale (PHSS; scale: 0-8) and skin dryness on the newly developed patient-reported Xerosis NRS (X-AD; scale: 0-10) at 24 weeks. About Dupixent Dupixent, which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.1 About Regeneron's VelocImmune Technology Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite ® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. Dupilumab Development Program Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. U.S. INDICATIONS DUPIXENT is a prescription medicine used: DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine. DUPIXENT is not used to treat any other forms of hives (urticaria). IMPORTANT SAFETY INFORMATION Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®. Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease, or chronic spontaneous urticaria, and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back. DUPIXENT can cause serious side effects, including: The most common side effects include: Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Use DUPIXENT exactly as prescribed by your healthcare provider. It's an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it's recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver. Please see accompanying full Prescribing Information including Patient Information. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit or follow Regeneron on LinkedIn, Instagram, Facebook or X. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company'), and actual events or results may differ materially from these forward-looking statements. Words such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Products') and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Product Candidates') and research and clinical programs now underway or planned, including without limitation Dupixent®(dupilumab); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, bullous pemphigoid, lichen simplex chronicus, and other potential indications; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including biosimilar versions of Regeneron's Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA®(aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website ( and its LinkedIn page ( Sanofi Disclaimers or Forward-Looking Statements This media update contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center . 1 Data on File
New York Times
29 minutes ago
- New York Times
Paramount, Where Protests Erupted, Has a Large Hispanic Population
As President Trump ordered at least 2,000 National Guard members to Los Angeles County on Saturday, some of the most active protests against immigration raids in the area were taking place near a Home Depot in Paramount, a small city some 25 miles southeast of the Hollywood sign. Law enforcement officers used flash-bang grenades and fired rubber bullets at demonstrators. The mood had been tense in the city ever since Mr. Trump took office for the second time with promises to deport thousands of undocumented immigrants. 'Since January, people have lived in fear,' said Jose Luis Solache, a state lawmaker who represents the area. 'We saw a decline in our schools' attendance, we saw a decline in people going to work.' Los Angeles County includes wealthy enclaves like Malibu and Beverly Hills, but also many communities like Paramount that have for decades attracted Latino immigrants who clean hotel rooms in tourist districts, manufacture clothes or work at the ports of Los Angeles and Long Beach. Paramount is one of about two dozen cities ringing Los Angeles's southeastern border, collectively known as 'the Gateway Cities.' Some 82 percent of Paramount's more than 51,000 residents are Hispanic and about 36 percent are foreign-born, according to census data. Its median household income is $70,900; across Los Angeles County, that number is roughly $87,800. 'All these cities — Bell Gardens, Bellflower, Paramount — they are full of working-class Latinos that were able to have a piece of the middle class,' said Hugo Soto-Martinez, a Los Angeles City Council member who previously worked as a labor organizer in the area. 'They're like Latino suburbs.' Trump administration officials have said that the federal government's immigration crackdown will increasingly focus on workplaces. Angelica Salas, the executive director of CHIRLA, an immigrant rights group in Los Angeles, said that the Paramount area's dense concentration of immigrants, including undocumented ones, most likely made it a ripe target for immigration enforcement raids. 'They don't care to go to a workplace or have warrants,' Ms. Salas said of federal immigration enforcement authorities. 'They just care that brown people are there.' Paramount and other Gateway Cities weren't always destinations for working families. In the early 20th century, they were agricultural areas. The two villages that would later combine to form Paramount were known as 'the Milk Shed of Los Angeles,' according to a city history on its website. In 1948, the city, which wouldn't be officially incorporated until 1957, was named Paramount for a main street running through town. The area was developed in the decades that followed. Factories and warehouses spread, alongside homes. According to the city history, in the early 1980s, a think tank called Paramount an 'urban disaster area.' But in recent years, Paramount has been revitalized as the children of immigrants have sought out more affordable homes and opened businesses. Now, young people catch up over elaborate horchata and coffee concoctions at Horchateria Rio Luna and belt their favorite songs during karaoke nights at Casa Adelita.
Fox News
34 minutes ago
- Fox News
Madonna, Leonardo DiCaprio name-dropped during Diddy's federal trial in explosive testimony
Explosive testimony in Sean "Diddy" Combs' trial featured a few A-list names during the fourth week. Madonna, Leonardo DiCaprio and Beyoncé are a few of the celebrities who came up as the prosecution witnesses continued to take the stand and testify against the rapper in his sex trafficking and racketeering case. Diddy's trial began May 12 with opening statements. Throughout the fourth week of testimony, the jury heard from the disgraced music mogul's ex-assistant "Mia," former Bad Boy Entertainment CFO Derek Ferguson, Cassie's friend Bryana Bongolan and Diddy's ex-girlfriend "Jane." Here's a look at the celebrities mentioned in court this week. After Diddy's assistant, who testified under the pseudonym Mia, was let go in March 2017, she was hired by pop star Madonna. The rapper's defense team had questioned Mia aboutwhether she'd worked in the "same industry" as before after being fired. When asked what the ex-assistant did for Madonna, Mia replied, "A myriad of things." "I was hired to help lead her film division," Diddy's former employee claimed on the stand. "She also needed help restructuring her internal executive team, then it morphed into multiple roles." Diddy's ex-assistant Mia mentioned both Leonardo DiCaprio and Mick Jagger in a text to her former boss that was read in court Monday. During her cross-examination, the disgraced music mogul's defense zeroed in on text messages Mia sent after she experienced alleged physical and sexual abuse by Combs. The former ex-assistant admitted the text messages she sent to Diddy after being terminated from her job were all positive. "Love you, too. And the only things to remember are the good times, and those are the only memories I have!! Ha ha ha, like f------ hysterical ones! I'll send you everything I've got! I remember even before you had videographers with us, I carried around the little iVid thing. I found those, too. Completely forgot about them. "So many magical hilarious things, like drinking 1942 on the Parrot Cay Beach and champagne under the Eiffel Tower at 4:00 a.m. in the dark; and singing with Jimmy at Interscope; and Mick Jagger trying to take me home, but I ran away; and Ibiza caves, where I got a seven-inch scar; and Hawaii 5.0, when you punched that d--- f--- for talking s--- to me; and launching Revolt; and that random underground Baccarat game where Jlolo wouldn't pay out and I stayed only, and you won 650 grand, and that little prick ran away from me, and Leo [DiCaprio] grabbed my pink bedazzled BlackBerry, and you said that Titanic mother f----- doesn't know s---. He won 10K, I won 650K. Ha ha ha. Gosh, there are trillions of stories that are amazing." Rihanna and Beyoncé were mentioned during Bryana Bongolan's testimony Wednesday. Cassie Ventura's friend claimed the two had been working on a clothing line with Diamond Supply Company. According to Bongolan, the two got out a few collections during a two-year period. However, the clothing lines didn't work out due to "internal" reasons at Diamond Supply Company. Cassie's friend agreed with Diddy's defense lawyer that the clothing lines didn't work out because the two were competing with Rihanna and Beyoncé. Film producer Judd Apatow was mentioned during testimony in Diddy's trial while the defense was showing text messages from the rapper's ex-assistant. The defense noted Mia sent the texts after the "Last Night" rapper had been violent with her for years. Mia left her job working for Diddy in 2017. On March 8, 2019, five months after the death of Diddy's longtime partner, Kim Porter, Mia reached out. "Just sending you all the love in the world," she wrote, adding a heart emoji. "Speaking of, you should watch Love on Netflix. Judd Apatow created it," she added in a separate text that same day. "It's superbad-esque funny." In another text message Diddy's ex-assistant sent to the rapper after he allegedly abused her, Mia mentioned actor Chadwick Boseman. "Thinking of you since I heard about Chad Boseman and our sick James Brown auditions," she wrote to Combs in 2020, years after she stopped working for him. The "Black Panther" star died from colon cancer at the age of 43. "Chad Boseman passed away, and we had done this – I don't know how to explain it," Mia further explained during her testimony. "He was auditioning for this role for the James Brown movie that Chad Boseman got, and, essentially, he put on his own production that was – or we put on his own production for, like, a week, and it was really intense. Yeah, that's it." Diddy then asked Mia if she had a copy of the James Brown audition tape.
